Werfen USA LLC

Werfen USA LLC, a Bedford, Massachusetts-based manufacturer of in vitro diagnostic equipment and clinical laboratory instrumentation, operates as a full-sized prime contractor supplying coagulation analyzers, blood gas analyzers, hematology testing systems, blood bank analyzers, and associated reagents and consumables to federal healthcare agencies on firm fixed-price and cost-per-reportable-result bases, competing without small business set-aside designations across a portfolio of 1,443 awards valued at $481.2 million.

The company's customer concentration is extreme and overwhelmingly focused on the Department of Veterans Affairs. The top five funding agencies account for 45 percent of awards by count, with Veterans Health Administration VISNs dominating the footprint: VISN 23 leads by award count at 208 awards ($13.3 million), but VISN 12 dominates by dollar value at 83 awards carrying $140.5 million in combined potential value—roughly 29 percent of Werfen's entire federal portfolio. VISN 15, VISN 10, VISN 17, and VISN 1 round out the top five by dollars, collectively representing $165.2 million. The Indian Health Service ($9.6 million across 114 awards) and the Defense Health Agency ($16.8 million across 92 awards) are secondary customers; together with the VA VISNs, these three customer segments anchor nearly 98 percent of Werfen's federal revenue. This concentration reflects Werfen's specialization in laboratory diagnostic equipment for federal healthcare delivery rather than diversified federal work.

Vehicle position is striking and monolithic. The Critical Analyzers, Laboratory GSA Schedule (FSS-66-III) carries 1,032 task orders worth $194.2 million—over 40 percent of Werfen's total federal potential value. The Multiple Award Schedule (MAS) holds 145 task orders valued at $47.4 million. The In Vitro Diagnostics, Reagents, Test GSA Schedule (FSS-65-VII) comprises 114 task orders at $15.2 million. Werfen also holds single-award and multiple indefinite delivery vehicles and blanket purchase agreements directly with individual VISNs, including a $3.06 million IDIQ with VISN 15 for coagulation analyzers and reagents (through August 2030), a $2.44 million BPA with VISN 2 for coagulation testing (through September 2030), and a $2.0 million single-award BPA with VISN 8 for coagulation cost-per-reportable-result services. All awards are full-and-open; Werfen does not compete under set-asides.

Recent activity shows sustained but moderating growth. Award volume grew from 113 in 2022 to 149 in 2024, then accelerated to 199 in 2025, before dropping to 81 in calendar year 2026 (through mid-September). This is consistent with a vendor hitting recompete cycles: 182 awards carrying $28.1 million in combined potential value will reach ultimate completion within the next twenty-four months, creating significant recompete exposure and opportunity for competitors. The most recent award dates from September 19, 2026, reflecting continued activity across multiple VISNs and the Defense Health Agency.

Representative prime contracts include delivery orders for autoimmune testing immunofluorescence assay and enzyme immunoassay services to VISN 17 ($184,417, September 2026), a $1.43 million VISN 1 supplies-and-rental agreement for in vitro diagnostic equipment (July 2026), coagulation testing cost-per-reportable-result services to VISN 8 valued at $412,211 (July 2026), a $671,622 single-award BPA for blood gas instruments with VISN 21 (April 2026), and blood gas analyzers to the Indian Health Service at $238,238 (August 2026). Across these awards, firm fixed-price and cost-per-reportable-result pricing models predominate; delivery orders and BPA calls are the dominant contract type, issued against standing master agreements that streamline procurement.

Werfen competes solely as a prime contractor—the source shows 100 percent prime awards and zero subcontract work. SCI-reported invoiced revenue is minimal ($16 thousand across three records spanning FY2022–FY2024, with zero FTEs recorded), indicating that Werfen's federal work is predominantly goods and products (analyzers, reagents, consumables) rather than labor-based service contracts above the $150,000 SCI reporting threshold. The hourly rates captured in the limited SCI data span a wide spectrum (10th percentile $43.85/hr, median $219.24/hr, 90th percentile $394.62/hr), reflecting the mix of technical labor and administrative overhead on rare service-contract deliverables. Werfen maintains no named subcontractor footprint and performs work from its Bedford, Massachusetts facility or at customer sites nationwide.

Werfen's federal footprint is a textbook example of a specialized medical device manufacturer locked into a dominant-customer relationship: the VA ecosystem. The company has built an entrenched position across multiple VISN networks through established GSA Schedule vehicles and single-award BPAs that provide operational continuity and predictable revenue. The recompete cliff of $28.1 million over the next twenty-four months signals both vulnerability (these contracts will be re-competed; some may be lost) and opportunity (competitors can target VISN recompetes directly). For federal contractors considering teaming, acquisition, or competitive positioning, Werfen represents a narrowly focused diagnostics supplier with deep VA relationships but limited diversification outside the healthcare procurement ecosystem.